Skip to main content
Premium Trial:

Request an Annual Quote

NIH Awards Four Microarray Centers $25M for Neuroscience Research

NEW YORK, June 20 (GenomeWeb News) - The National Institutes of Health has awarded a consortium of four microarray core facilities a total of $25 million over five years to support gene expression analysis as part of the NIH Neuroscience Blueprint.

 

The centers in the NIH Neuroscience Microarray Consortium are located at the University of California at Los Angeles, the Translational Genomics Research Institute, Yale University, and Duke University. Each center provides access to different array platforms.

 

The Microarray Consortium supports around 10,000 investigators, according to a statement issued by TGen. It was initially funded in 2002 with $9 million from the National Institute of Neurological Disorders and Stroke and the National Institute of Mental Health. The new award is supported by these two institutes as well as thirteen other NIH Neuroscience Blueprint institutes.

 

The consortium worked with 5 AM Solutions, a software company based in Phoenix, Ariz., to create a central database for the data it is generating. Further information about the consortium is available here.

 

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.